Coherus Oncology, Inc. — Director's Dealing 2019

Jun 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Coherus BioSciences, Inc. (CHRS)
CIK: 0001512762
Period of Report: 2019-06-18

Reporting Person: Viret Jean-Frederic (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-18	Common Stock, $0.0001 par value	S	3000	$19.3088	Disposed	12180	Direct
2019-06-19	Common Stock, $0.0001 par value	S	667	$20.00	Disposed	11513	Direct
2019-06-19	Common Stock, $0.0001 par value	M	3159	$10.05	Acquired	14672	Direct
2019-06-19	Common Stock, $0.0001 par value	S	3059	$20.3224	Disposed	11613	Direct
2019-06-19	Common Stock, $0.0001 par value	S	100	$20.81	Disposed	11513	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-19	Stock Option (Right to Buy)	$10.05	M	3159	Disposed	2028-02-01	Common Stock (3159)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.

F2: The transaction was executed in multiple trades in prices ranging from $19.04 to $19.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F3: Includes 1,995 shares acquired on May 15, 2019 pursuant to Issuer's employee stock purchase plan.

F4: The transaction was executed in multiple trades in prices ranging from $19.75 to $20.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F5: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.